West Pharmaceutical Services, Inc. (WST) 2026 KeyBanc Capital Markets Healthcare Virtual Forum March 18, 2026 1:30 PM EDT
Company Participants
Robert McMahon – Senior VP & CFO
Conference Call Participants
Paul Knight – KeyBanc Capital Markets Inc., Research Division
Anna Snopkowski – KeyBanc Capital Markets Inc., Research Division
Presentation
Paul Knight
KeyBanc Capital Markets Inc., Research Division
This is Paul Knight, the analyst covering life science at KeyBanc Capital Markets. With me today is Anne Snopkowski, who’s on my team as well. we’ll be running some Q&A. And then we have, of course, Bob McMahon, the Chief Financial Officer of West Pharma; John Sweeney, Head of Investor Relations.
But that kind of pops into my first question, Bob. Agilent, of course, very, very well-known firm, I followed it since the ’99 spin, I believe, from HP. What do you like about the West business now that you’ve been here a little bit?
Question-and-Answer Session
Robert McMahon
Senior VP & CFO
Yes. Yes, Paul, Great. Thanks to you and Anna for having us. We really appreciate it. And what I’d say is the thing that’s really super exciting about West is I think it’s a business model that’s fairly rarely matched in the industry. And when I think about that, a business that’s got a very strong market share 70% to 75%, kind of, market share with even more opportunities ahead of us as we move into kind of biologics, where we have even a higher participation rate and the durability of the business long term.
So when we think about the competitive moat that we have once we’re spec-ed into a product, we are on that product for the life of that product. And so it’s very rare that we lose a molecule. And so whether that be a branded molecule or even
